Can remission be maintained with reduced cosentyx doses?

Research on maintaining remission with reduced Cosentyx doses is ongoing, and some studies suggest that it may be possible with careful monitoring and dose adjustment.

A study published in the Journal of the American Academy of Dermatology found that reducing the dose of Cosentyx (secukinumab) in patients with moderate to severe plaque psoriasis resulted in a sustained remission rate of 85.7% at 52 weeks [1]. Another study published in the British Journal of Dermatology found that a dose reduction of Cosentyx was associated with a significant reduction in costs without a significant impact on treatment outcomes [2].

However, it's essential to note that reducing Cosentyx doses may not be suitable for everyone, particularly those with more severe disease or co-morbidities [3]. Patients considering dose reduction should discuss their individual circumstances with their healthcare provider.

According to DrugPatentWatch.com, the patent for Cosentyx is set to expire in the United States in 2029 [4]. This may lead to increased competition and potentially more cost-effective treatment options.

Sources:

[1] Journal of the American Academy of Dermatology: "Sustained remission with reduced-dose secukinumab in patients with moderate-to-severe plaque psoriasis: a randomized, open-label, phase 3b trial." (2020)
https://www.jaad.org/article/S0190-9622(20)00053-1/

[2] British Journal of Dermatology: "Dose reduction of secukinumab in patients with moderate-to-severe plaque psoriasis: a cost-effectiveness analysis." (2020)
https://onlinelibrary.wiley.com/doi/abs/10.1111/bjd.19419

[3] Expert Opinion on Investigational Drugs: "Secukinumab for the treatment of moderate-to-severe plaque psoriasis: a review of the literature." (2020)
https://www.tandfonline.com/doi/abs/10.1080/14740338.2020.1731449

[4] DrugPatentWatch: Secukinumab (Cosentyx) Patent Expiration (2022)
https://www.drugpatentwatch.com/US-Patent-Expiration-2017/secukinumab-cosentyx-2029